Insulin delivery is a crucial component of a closed-loop system aiming at the development of an artificial pancreas. The intravenous route, which has been used in the bedside artificial pancreas model for 30 years, has clear advantages in terms of pharmacokinetics and pharmacodynamics, but cannot be used in any ambulatory system so far. Subcutaneous (SC) insulin infusion benefits from the broad expansion of insulin pump therapy that promoted the availability of constantly improving technology and fast-acting insulin analog use. However, persistent delays of insulin absorption and action, variability and shortterm stability of insulin infusion from SC-inserted catheters generate effectiveness and safety issues in view of an ambulatory, automated, glucose-controlled, artificial beta cell. Intraperitoneal insulin delivery, although still marginally used in diabetes care, may offer an interesting alternative because of its more-physiological plasma insulin profiles and sustained stability and reliability of insulin delivery.
RenardE. Implantable closed loop glucose-sensing and insulin delivery: The future for insulin pump therapy. Curr Opin Pharmacol.2002; 2 (6): 708–16.
2.
KlonoffDC. The artificial pancreas: How sweet engineering will solve bitter problems. J Diabetes Sci Technol.2007; 1 (1): 72–81.
3.
AlbisserAMLeibelBSEwartTFDavidovacZBotzCKZinggWSchipperHGanderR. Clinical control of diabetes by the artificial pancreas. Diabetes.1974; 23 (5): 397–404.
4.
MirouzeJSelamJLPhamTCCavadoreD. Evaluation of exogenous insulin homeostasis by the artificial pancreas in insulin-dependent diabetes. Diabetologia.1977; 13 (3): 273–8.
5.
SelamJLCharlesMA. Devices for insulin administration. Diabetes Care.1990; 13 (9): 955–79.
6.
BlackshearPJShulmanGIRoussellAMNathanDMMinakerKLRoweAMRobbinsDCCohenAM. Metabolic response to three years of continuous, basal rate intravenous insulin infusion in type II diabetic patients. J Clin Endocrinol Metab.1985; 61 (4): 753–60.
7.
SelamJLMicossiPDunnFLNathanDM. Clinical trial of programmable implantable insulin pumps for type 1 diabetes. Diabetes Care.1992; 15 (7): 877–85.
8.
HoweyDCBowsherRRBrunelleRLWoodworthJR. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes.1994; 43 (3): 396–402.
9.
MelkiVRenardELassmann-VagueVBoivinSGuerciBHanaire-BroutinHBringerJBelicarPJeandidierNMeyerLBlinPAugendre-FerranteBTauberJP. Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care.1998; 21 (6): 977–82.
SteilGMRebrinKDarwinCHaririFSaadMF. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes.2006; 55 (12): 3344–50.
12.
WeinzimerSASteilGMSwanKLDziuraJKurtzNTamborlaneWV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care.2008; 31 (5): 934–9. Epub 2008 Feb 5.
13.
SteilGMPanteleonAERebrinK. Closed-loop insulin delivery-the path to physiological glucose control. Adv Drug Deliv Rev.2004; 56 (2): 125–44.
BotzCKLeibelBSZinggWGanderREAlbisserAM. Comparison of peripheral and portal routes of insulin infusion by a computer-controlled insulin infusion system (artificial endocrine pancreas). Diabetes.1976; 25 (8): 691–700.
16.
GiaccaACaumoAGalimbertiGPetrellaGLibrentiMCScaviniMPozzaGMicossiP. Peritoneal and subcutaneous absorption of insulin in type 1 diabetic subjects. J Clin Endocrinol Metab.1993; 77 (3): 738–42.
17.
NathanDMDunnFLBruchJMcKitrickCLarkinMHagganCLavin-TompkinsJNormanDRogersDSimonD. Postprandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients. Am J Med.1996; 100 (4): 412–7.
18.
SaudekCDSelamJLPittHAWaxmanKRubioMJeandidierNTurnerDFischellRECharlesMA. A preliminary trial of the programmable implantable medication system for insulin delivery. N Engl J Med.1989; 321 (9): 574–9.
19.
Hanaire-BroutinHBroussolleCJeandidierNRenardEGuerciBHaardtMJLassmann-VagueV. Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM. A multicenter study. The EVADIAC Study Group. Diabetes Care.1995; 18 (3): 388–92.
20.
CatargiBMeyerLMelkiVRenardEJeandidierN; for the EVADIAC Study Group. Comparison of blood glucose stability and HbA1c between implantable insulin pumps using U400 HOE 21PH insulin and external pumps using lispro in type 1 diabetic patients: A pilot study. Diabetes Metab.2002; 28 (2): 133–7.
21.
BroussolleCJeandidierNHanaire-BroutinH. French multicentre experience with implantable insulin pumps. The EVADIAC Study Group. Lancet.1994; 343 (8896): 514–5.
22.
SelamJLRaymondMJacqueminJLOrsettiARichardJLMirouzeJ. Pharmacokinetics of insulin infused intra-peritoneally via portable pumps. Diabetes Metab.1985; 11 (3): 170–3.
23.
OskarssonPRLinsPEBackmanLAdamsonUC. Continuous intraperitoneal insulin infusion partly restores the glucagon response to hypoglycemia in type 1 diabetic patients. Diabetes Metab.2000; 26 (2): 118–24.
24.
OskarssonPRLinsPEWallberg-HenrikssonHAdamsonUC. Metabolic and hormonal responses to exercise in type 1 diabetic patients during continuous subcutaneous, as compared to continuous intraperitoneal, insulin infusion. Diabetes Metab.1999; 25 (6): 491–7.
25.
RenardEBouteleauSJacques-ApostolDLautonDGibert-BouletFCostalatGBringerJJaffiolC. Insulin underdelivery from implanted pumps using peritoneal route. Determinant role of insulin-pump compatibility. Diabetes Care.1996; 19 (8): 812–7.
26.
ShishkoPIKovalevPAGoncharovVGZajarnyIU. Comparison of peripheral and portal (via the umbilical vein) routes of insulin infusion in IDDM patients. Diabetes.1982; 41 (9): 1042–9.
RenardECostalatGChevassusHBringerJ. Closed loop insulin delivery using implanted insulin pumps and sensors in type 1 diabetic patients. Diabetes Res Clin Pract.2006; 74 (Suppl 2): S173–7.
29.
OlsenCLChanETurnerDSIravaniMNagyMSelamJLWongNDWaxmanKCharlesMA. Insulin antibody responses after long-term intraperitoneal insulin administration via implantable programmable insulin delivery systems. Diabetes Care.1994; 17 (3): 169–76.
